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ORIGINAL ARTICLE
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Background: Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of patients with cancer and coronavirus 2019 (COVID19) reported to the COVID-19 and Cancer Consortium (CCC19) to identify prognostic clinical factors, including
laboratory measurements and anticancer therapies.
Patients and methods: Patients with active or historical cancer and a laboratory-conﬁrmed SARS-CoV-2 diagnosis
recorded between 17 March and 18 November 2020 were included. The primary outcome was COVID-19 severity
measured on an ordinal scale (uncomplicated, hospitalized, admitted to intensive care unit, mechanically ventilated,
died within 30 days). Multivariable regression models included demographics, cancer status, anticancer therapy and
timing, COVID-19-directed therapies, and laboratory measurements (among hospitalized patients).
Results: A total of 4966 patients were included (median age 66 years, 51% female, 50% non-Hispanic white); 2872
(58%) were hospitalized and 695 (14%) died; 61% had cancer that was present, diagnosed, or treated within the
year prior to COVID-19 diagnosis. Older age, male sex, obesity, cardiovascular and pulmonary comorbidities, renal
disease, diabetes mellitus, non-Hispanic black race, Hispanic ethnicity, worse Eastern Cooperative Oncology Group
performance status, recent cytotoxic chemotherapy, and hematologic malignancy were associated with higher
COVID-19 severity. Among hospitalized patients, low or high absolute lymphocyte count; high absolute neutrophil
count; low platelet count; abnormal creatinine; troponin; lactate dehydrogenase; and C-reactive protein were
associated with higher COVID-19 severity. Patients diagnosed early in the COVID-19 pandemic (January-April 2020)
had worse outcomes than those diagnosed later. Speciﬁc anticancer therapies (e.g. R-CHOP, platinum combined with
etoposide, and DNA methyltransferase inhibitors) were associated with high 30-day all-cause mortality.
Conclusions: Clinical factors (e.g. older age, hematological malignancy, recent chemotherapy) and laboratory
measurements were associated with poor outcomes among patients with cancer and COVID-19. Although further
studies are needed, caution may be required in utilizing particular anticancer therapies.
Clinical trial identiﬁer: NCT04354701
Key words: SARS-CoV2, neoplasm, cancer, anticancer therapy, laboratory measurements, outcomes
INTRODUCTION
The severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) pandemic has resulted in at least 1.5 million deaths
worldwide.1,2 Patients with cancer may have increased risk
for SARS-CoV-2 infection3-5 and worse outcomes.6-13 Estimates of 30-day mortality associated with coronavirus 2019
(COVID-19) for patients with cancer range from 13% to
33%,6,7 compared with 0.5% to 2% in the general
population.1,14
Patients with cancer comprise a heterogeneous population, and a better understanding of speciﬁc risk factors
associated with poor outcomes may help guide clinical
management. The COVID-19 and Cancer Consortium (CCC19)
is an international consortium that collects data on patients
with cancer and COVID-19.6,15,16 Studies from CCC19 and
other cohorts have suggested that older age, male sex,
smoking status, worse performance status (PS), presence of
comorbidities, hematological malignancies, and active cancer
are associated with more severe outcomes.6-9,13
Prior studies were limited by modest statistical power.
There is also conﬂicting data regarding the impact of timing
and modality of recent anticancer therapy on COVID-19
severity.7,8,17 In addition, few studies have investigated
the role of laboratory measurements as possible prognostic
indicators, particularly among patients with cancer hospitalized with COVID-19.
Leveraging detailed information from almost 5000 patients with COVID-19 and cancer, we evaluated the hypothesis that speciﬁc demographic characteristics, clinical
factors, and laboratory measurements would be associated
788
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with higher COVID-19 severity. We also explored the impact
of speciﬁc anticancer therapies on COVID-19 severity and
30-day all-cause mortality.
METHODS
Study design
CCC19 maintains a centralized multi-institution registry of
patients with COVID-19 who have a current or past diagnosis of cancer. Details of the schema and data elements
have been previously described.6,13 Study data are collected
and managed using REDCap software hosted at Vanderbilt
University Medical Center.18,19
Reports were accrued from 17 March to 18 November
2020 and included patients who had a laboratory-conﬁrmed
diagnosis of SARS-CoV-2 by PCR and/or serology. Patients
with noninvasive cancers including nonmelanoma skin
cancer, in situ carcinoma (except bladder carcinoma in situ),
or precursor hematologic neoplasms (e.g. monoclonal
gammopathy of undetermined signiﬁcance) were excluded.
Reports with low-quality data (quality score >4 using our
previously deﬁned metric20; Supplementary Table S1,
available at https://doi.org/10.1016/j.annonc.2021.02.024)
or incomplete outcome ascertainment, resulting in unknown status of the primary outcome, were also excluded.
This study was exempt from Institutional Review Board
(IRB) review (VUMC IRB#200467) and was approved by
IRBs at participating sites per respective institutional policy.
This ongoing study is registered on ClinicalTrials.gov
(NCT04354701).
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Outcome deﬁnitions
The primary outcome was a ﬁve-level ordinal scale of
COVID-19 severity based on a patient’s most severe reported disease status: none of the following complications
(hereafter, uncomplicated); admitted to the hospital,
admitted to an intensive care unit (ICU), mechanically
ventilated at any time after COVID-19 diagnosis; or died
from any cause within 30 days of COVID-19 diagnosis. We
performed a secondary analysis of 30-day all-cause mortality and a descriptive analysis of patterns of anticancer
therapy received within 3 months of COVID-19 diagnosis.
Prognostic factors
Potential prognostic variables were identiﬁed a priori and
included age; sex; race/ethnicity; country of patient residence (United States versus non-United States); month of
COVID-19 diagnosis (January-April, May-August, SeptemberNovember; year 2020); smoking status; obesity; cardiovascular and pulmonary comorbidities; renal disease; diabetes
mellitus; Eastern Cooperative Oncology Group (ECOG) PS;
type of malignancy (solid tumor, hematological neoplasm);
cancer status at time of COVID-19 diagnosis; timing of the
most recent anticancer therapy; modality of anticancer
therapy received within 3 months of COVID-19 diagnosis;
and anti-COVID-19 treatments. Cancer status was deﬁned
as remission or no evidence of disease versus active disease, with active further deﬁned as responding to therapy,
stable, or progressing. Timing of anticancer therapy was
categorized as never treated, 0-4 weeks, 1-3 months, and
>3 months prior to COVID-19 diagnosis. Anticancer modalities were deﬁned as cytotoxic chemotherapy, immunotherapy, targeted therapy, endocrine therapy, locoregional
therapy (radiation and/or surgery), and other
(Supplementary Table S2, available at https://doi.org/10.
1016/j.annonc.2021.02.024). Anti-COVID-19 treatments
included hydroxychloroquine, corticosteroids, remdesivir,
and other (Supplementary Table S3, available at https://doi.
org/10.1016/j.annonc.2021.02.024).
Survey respondents were instructed to report the earliest
measured laboratory measurements during the COVID-19
disease course. Laboratory measurements included absolute lymphocyte count (ALC), absolute neutrophil count
(ANC), platelet count, creatinine, D-dimer, troponin,
lactate dehydrogenase (LDH), and C-reactive protein (CRP).
Hematological measurements (ALC, ANC, platelets) were
recorded as high, normal, or low; nonhematological measurements were deﬁned as normal or abnormal. Except for
low ALC, which was centrally deﬁned as ALC <1500/ml,
ascertainment of upper and lower limits of normal was left
to the discretion of survey respondents.
Statistical methods
All statistical methods were speciﬁed before database lock
(18 November 2020) and the subsequent initiation of the
analysis.
Standard descriptive statistics were used to summarize
baseline prognostic factors overall and stratiﬁed by levels of
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the ordinal COVID-19 severity outcome. Adjusted odds
ratios and 95% conﬁdence intervals for COVID-19 severity
and 30-day mortality were estimated from multivariable
ordinal and binary logistic regression models, respectively.21
Exploratory analyses with smoothing splines were used
to determine the association of age (as a continuous
variable) with outcomes,22 which appeared nonlinear
(Supplementary Figure S1, available at https://doi.org/10.
1016/j.annonc.2021.02.024). A linear regression spline
with a knot at 40 years, which allowed a different linear
association less than and greater than 40 years, provided an
adequate ﬁt. All other covariates were categorical.
For analyses among all patients, we included all prespeciﬁed covariates in a single model, given a sufﬁcient
number of events (and corresponding degrees of freedom)
to enable full multivariable models. In the primary analysis
for COVID-19 severity, we did not adjust for anti-COVID-19
treatments due to suspected confounding by indication16;
these were adjusted for in a sensitivity analysis. Results
between minimally adjusted (age, sex, and race/ethnicity)
and fully adjusted models, variance inﬂation factors, and
clinical judgment were used to assess stability of the results.
We considered interactions among speciﬁc comorbidities
(cardiovascular, pulmonary, renal disease), speciﬁc antiCOVID-19 treatments (hydroxychloroquine, corticosteroids,
other), speciﬁc anticancer therapies (cytotoxic chemotherapy, immunotherapy, targeted therapy), and between
timing and modality of anticancer therapy.
Associations of laboratory measurements with outcomes
were assessed among hospitalized patients due to current
common clinical practice to avoid a laboratory blood draw
for outpatients.23 Because of the reduced sample size, we
adjusted for a smaller set of potential clinical confounders:
age, sex, race/ethnicity, country of patient residence, month
of COVID-19 diagnosis, type of malignancy, cancer status,
and active anticancer therapy. No interactions were
considered for this analysis.
Multiple imputation using additive regression, bootstrapping, and predictive mean matching was used to
impute missing and unknown data for all variables included
in the analysis,24 with the following exceptions: unknown
ECOG PS and unknown cancer status were included as
‘unknown’ categories; and laboratory values were imputed
only among hospitalized patients. Separate imputation
models were developed for the full cohort (10 iterations;
missingness rates were <5%) and the hospitalized cohort
(20 iterations; missingness rates for laboratory values were
>10%).
We conducted an exploratory analysis of speciﬁc anticancer drug exposures, which are collected in optional freetext ﬁelds. Two curators (JLW and XL) independently
abstracted the ﬁelds for all patients with systemic anticancer therapy reported (cytotoxic chemotherapy, immunotherapy, endocrine therapy, and/or targeted therapy)
within 3 months prior to COVID-19 diagnosis; disagreements were resolved by consensus. Speciﬁc drugs were
grouped by similar mechanisms of action (Supplementary
Table S2, available at https://doi.org/10.1016/j.annonc.
https://doi.org/10.1016/j.annonc.2021.02.024
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2021.02.024) based on consensus among authors. The results were visualized using UpSet plots.25
Analyses were performed in R version 4.0.3 (R Foundation for Statistical Computing, Vienna, Austria), including
the Hmisc, rms, and UpSetR26 extension packages.
RESULTS
A total of 6968 reports were evaluable in the REDCap
database and 4966 were included in our analysis after exclusions (Supplementary Figure S2, available at https://doi.
org/10.1016/j.annonc.2021.02.024). Among these patients,
who had a median follow-up of 42 days [interquartile range
(IQR) 22-90 days], 2872 (58%) were hospitalized during their
COVID-19 course (Table 1). The median age of the entire
cohort and hospitalized subgroup was 66 (IQR 56-76) and
70 (IQR 60-79) years, respectively. Approximately half of the
patients were female and non-Hispanic white in each group,
while non-Hispanic black patients represented 22% and
24%, respectively. Approximately 80% had solid tumors,
51% had cancer in remission, and 40% received anticancer
therapy within 3 months of COVID-19 diagnosis. Altogether,
61% had cancer that was present, active, or treated within
the past year. Additional baseline characteristics are summarized in Table 1.
Supplementary Table S4, available at https://doi.org/10.
1016/j.annonc.2021.02.024, provides unadjusted rates of
hospitalization and 30-day mortality. Of note, the 30-day
mortality rate (95% CI) for patients diagnosed with
COVID-19 during January-April, May-August, and
September-November was 21% (20%-23%), 10% (9%-11%),
and 7% (5%-10%), respectively.
COVID-19 severity
Of the 4966 patients, 2072 had an uncomplicated disease
course (Table 2). For the 2894 patients with complications,
1675 were admitted to the hospital but did not require ICU
care or mechanical ventilation and did not die. An additional 232 were admitted to the ICU without mechanical
ventilation, 292 required mechanical ventilation, and 695
died within 30 days. Patients who died were older (median
age 75 versus 61-69 years for other outcomes). Males had
worse COVID-19 severity compared with females, as indicated by greater proportions of males among those who
received mechanical ventilation or died. Table 2 and
Supplementary Table S5, available at https://doi.org/10.
1016/j.annonc.2021.02.024, provide summaries stratiﬁed
by the ordinal outcome for the entire cohort and the hospitalized subgroup, respectively.
Multivariable analysis revealed higher COVID-19 severity
among patients older than 40 years, males, and nonHispanic black and Hispanic patients compared with nonHispanic white patients (Table 3). In addition, obesity,
cardiovascular and pulmonary comorbidities, renal disease,
diabetes mellitus, worse ECOG PS, and hematological malignancy were associated with higher COVID-19 severity.
Active and progressing cancer, recent active cytotoxic
chemotherapy, and COVID-19-directed treatments were
790
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also associated with higher severity. Notably, noncytotoxic
systemic anticancer therapies including immunotherapy,
targeted therapy, and endocrine therapy were not associated with higher COVID-19 severity. Of the 483 patients
receiving endocrine therapy, 214 (44%) were in remission,
which was a higher proportion than for those receiving
cytotoxic chemotherapy (11%), targeted therapy (15%), or
immunotherapy (6%).
More recent diagnosis of COVID-19 compared with
diagnosis earlier in the pandemic (between January and
April) was associated with lower COVID-19 severity. Significant interactions were observed among anti-COVID-19
treatments (Supplementary Table S6, available at https://
doi.org/10.1016/j.annonc.2021.02.024). However, there
were no meaningful interactions among medical comorbidities, anticancer therapies, or between timing of anticancer therapy and modality of anticancer therapies
(Supplementary Table S7, available at https://doi.org/10.
1016/j.annonc.2021.02.024).
Many characteristics associated with higher COVID-19
severity, including cytotoxic chemotherapy, were also
associated with 30-day mortality (Table 3). Factors such as
Hispanic ethnicity and cardiovascular comorbidities had a
weaker association that was no longer statistically signiﬁcant. COVID-19-directed treatments had a substantial
attenuation of the association in the 30-day mortality
analysis, although all retained statistical signiﬁcance.
Laboratory measurements among hospitalized patients
Laboratory measurements collected during SARS-CoV-2
diagnosis were analyzed among the hospitalized subgroup
of 2872 patients (Figure 1, Supplementary Table S8, available at https://doi.org/10.1016/j.annonc.2021.02.024).
High ALC; low ALC; high ANC; and low platelets; as well as
abnormal levels of creatinine; troponin; or LDH; were each
associated with higher COVID-19 severity and 30-day mortality. Abnormal CRP was associated with higher COVID-19
severity.
Anticancer therapies
Of the 1803 patients receiving systemic anticancer therapy
within 3 months of COVID-19 diagnosis, 1626 (90%) had
extractable free-text drug exposure with 125 distinct drugs/
classes reported. Most exposures (n ¼ 856, 53%) were to a
single drug or class; 357 (22%) patients received at least
three drugs in combination. Drug/class exposures noted in
at least 10 patients are shown in Figure 2. The three
treatment regimens with the lowest and highest observed
30-day and overall all-cause mortality are described in
Table 4. Platinum-etoposide, R-CHOP-like, and DNA methyltransferase inhibitor regimens were associated with the
highest observed 30-day and overall all-cause mortality.
DISCUSSION
COVID-19 poses a substantial risk to patients with cancer. It
is essential to understand factors associated with high risk
of adverse outcomes to inform clinical decision making. In
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Table 1. Baseline prognostic factors among all patients and hospitalized
patients

Median agea, years (IQR)
Sex
Female
Male
Missing/unknown
Race and ethnicityb
Non-Hispanic white
Non-Hispanic black
Hispanic
Other
Missing/unknown
Smoking status
Never
Ever
Missing/unknown
Obesity status
Not obese
Obese
Missing/unknown
Comorbiditiesb
Cardiovascular
Pulmonary
Renal disease
Diabetes mellitus
Missing/unknown
ECOG performance status
0
1
2
Unknown
Missing
Type of malignancyb
Solid tumor
Hematological neoplasm
Cancer status
Remission or no evidence of disease
Active and responding
Active and stable
Active and progressing
Unknown
Missing
Timing of anticancer therapy
Never treated
0-4 weeks
1-3 months
>3 months
Missing/unknown
Modality of active anticancer therapyb,c
None
Cytotoxic chemotherapy
Immunotherapy
Targeted therapy
Endocrine therapy
Locoregional therapy
Other
Missing/unknown
Anti-COVID-19 treatmentb
None
Remdesivir
Hydroxychloroquine
Corticosteroids
Other
Missing/unknown
Country of patient residence
United States
Outside United States

All patients

Hospitalized
patients

(n ¼ 4966)

(n ¼ 2872)

66 (56-76)

70 (60-79)

2527 (51)
2436 (49)
3 (<1)

1323 (46)
1546 (54)
3 (<1)

2485
1068
722
578
113

1371
697
390
359
55

(50)
(22)
(15)
(12)
(2)

(48)
(24)
(14)
(12)
(2)

2615 (53)
2161 (44)
190 (4)

1356 (47)
1386 (48)
130 (5)

3220 (65)
1704 (34)
42 (1)

1909 (66)
944 (33)
19 (1)

1582
1091
831
1385
56

(32)
(22)
(17)
(28)
(1)

1175
762
644
994
26

(41)
(27)
(22)
(35)
(1)

1731
1296
806
1121
12

(35)
(26)
(16)
(23)
(<1)

725
794
675
671
7

(25)
(28)
(24)
(23)
(<1)

4021 (81)
1097 (22)

2260 (79)
717 (25)

2546
556
813
613
426
12

(51)
(11)
(16)
(12)
(9)
(<1)

1366
293
467
452
283
11

(48)
(10)
(16)
(16)
(10)
(<1)

413
1609
375
2344
225

(8)
(32)
(8)
(47)
(5)

252
907
231
1324
158

(9)
(32)
(8)
(46)
(6)

2807
802
248
693
483
422
33
176

(57)
(16)
(5)
(14)
(10)
(8)
(1)
(4)

1625
491
137
426
229
249
18
110

(57)
(17)
(5)
(15)
(8)
(9)
(1)
(4)

2816
438
829
708
1166
259

(57)
(9)
(17)
(14)
(23)
(5)

1048
435
796
634
1023
143

(36)
(15)
(28)
(22)
(36)
(5)

4739 (95)
227 (5)

2714 (94)
158 (6)

Continued
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Table 1. Continued

Month of COVID-19 diagnosis
January-April
May-August
September-November
Missing/unknown
Absolute lymphocyte countd
Low
Normal
High
Missing/unknown
Absolute neutrophil countd
Low
Normal
High
Missing/unknown
Platelet countd
Low
Normal
High
Missing/unknown
Creatinined
Normal
Abnormal
Missing/unknown
D-dimerd
Normal
Abnormal
Missing/unknown
Troponind
Normal
Abnormal
Missing/unknown
Lactate dehydrogenased
Normal
Abnormal
Missing/unknown
C-reactive proteind
Normal
Abnormal
Missing/unknown

All patients

Hospitalized
patients

(n ¼ 4966)

(n ¼ 2872)

1927
2508
433
98

(39)
(51)
(9)
(2)

1284
1325
211
52

(45)
(46)
(7)
(2)

d
d
d
d

1402
891
74
505

(49)
(31)
(3)
(18)

d
d
d
d

217
1739
474
442

(8)
(61)
(17)
(15)

d
d
d
d

733
1675
119
345

(26)
(58)
(4)
(12)

d
d
d

1498 (52)
1049 (37)
325 (11)

d
d
d

236 (8)
1321 (46)
1315 (46)

d
d
d

983 (34)
608 (21)
1281 (45)

d
d
d

358 (12)
1128 (39)
1386 (48)

d
d
d

137 (5)
1434 (50)
1301 (45)

Data presented as n (%) unless otherwise indicated. The ‘Missing/unknown’ category
indicates either missingness due to nonresponse for optional survey questions or a
response of unknown; an unknown category was provided for all survey questions.
COVID-19, coronavirus disease 2019; ECOG, Eastern Cooperative Oncology Group;
IQR, interquartile range.
a
For patients younger than 18 years (n ¼ 9), age was truncated to 18 years; for
patients older than 89 years (n ¼ 161), age was truncated to 90 years. Truncation
was done in concordance with the Health Insurance Portability and Accountability
Act of 1996 (HIPAA) and to reduce the risk of re-identiﬁability.
b
Percentages could sum to >100% because categories are not mutually exclusive.
c
Within 3 months of COVID-19 diagnosis.
d
Laboratory data were systemically not collected for nonhospitalized patients.

this study, we used a novel ordinal outcome of COVID-19
severity and a cohort of almost 5000 patients with cancer
to identify demographic factors (age, male sex, race/
ethnicity), clinical factors (comorbidities, ECOG PS, hematological malignancy, active and progressing cancer, recent
cytotoxic chemotherapy), and laboratory measurements
(high or low ALC; high ANC; low platelets; abnormal creatinine, troponin, or LDH) associated with higher COVID-19
severity. While these data can certainly inform providers
regarding prognostic factors and risk stratiﬁcation, and also
signiﬁcantly broaden our understanding in this important
https://doi.org/10.1016/j.annonc.2021.02.024
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Table 2. Baseline prognostic factors stratiﬁed by levels of COVID-19 severitya among all patients
Prognostic factor

No complications

Admitted to hospital

(n ¼ 2072, 42%)

(n ¼ 1675, 34%)

Median ageb, years (IQR)
61 (50-70)
Sex
Female
1193 (58)
Male
879 (42)
Missing/unknown
0 (0)
Race and ethnicityc
Non-Hispanic white
1100 (53)
Non-Hispanic black
369 (18)
Hispanic
328 (16)
Other
217 (10)
Missing/unknown
58 (3)
Smoking status
Never
1248 (60)
Ever
764 (37)
Missing/unknown
60 (3)
Obesity status
Not obese
1293 (62)
Obese
756 (36)
Missing/unknown
23 (1)
Comorbiditiesc
Cardiovascular
393 (19)
Pulmonary
323 (16)
Renal disease
179 (9)
Diabetes mellitus
385 (19)
Missing/unknown
30 (1)
ECOG performance status
0
1004 (48)
1
499 (24)
2
115 (6)
Unknown
449 (22)
Missing
5 (<1)
Type of malignancyc
Solid tumor
1744 (84)
Hematological neoplasm
373 (18)
Cancer status
Remission
1173 (57)
Active and responding
262 (13)
Active and stable
344 (17)
Active and progressing
153 (7)
Unknown
139 (7)
Missing
1 (<1)
Timing of anticancer therapy
Never treated
159 (8)
0-4 weeks
697 (34)
1-3 months
139 (7)
>3 months
1012 (49)
Missing/unknown
65 (3)
Modality of active anticancer therapyc,d
None
1171 (57)
Cytotoxic chemotherapy
305 (15)
Immunotherapy
108 (5)
Targeted therapy
264 (13)
Endocrine therapy
252 (12)
Locoregional therapy
173 (8)
Other
15 (1)
Missing/unknown
65 (3)
c
Anti-COVID-19 treatment
None
1752 (85)
Remdesivir
<5 (<1)
Hydroxychloroquine
32 (2)
Corticosteroids
73 (4)
Other
142 (7)
Missing/unknown
112 (5)
Country of patient residence
United States
2004 (97)
Outside United States
68 (3)

69 (59-78)

Admitted to ICU
(n ¼ 232, 5%)
66.5 (58-76)

Received mechanical
ventilation

Died within 30 days

(n ¼ 292, 6%)
66 (57-72.25)

(n ¼ 695, 14%)
75 (66-83)

832 (50)
841 (50)
2 (<1)

109 (47)
123 (53)
0 (0)

111 (38)
180 (62)
1 (<1)

282 (41)
413 (59)
0 (0)

802
389
239
211
34

116
51
27
36
2

125
76
46
38
7

342
183
82
76
12

(48)
(23)
(14)
(13)
(2)

(50)
(22)
(12)
(16)
(1)

(43)
(26)
(16)
(13)
(2)

(49)
(26)
(12)
(11)
(2)

842 (50)
768 (46)
65 (4)

105 (45)
113 (49)
14 (6)

154 (53)
126 (43)
12 (4)

266 (38)
390 (56)
39 (6)

1125 (67)
538 (32)
12 (1)

148 (64)
82 (35)
2 (1)

165 (57)
125 (43)
2 (1)

489 (70)
203 (29)
3 (<1)

629
414
331
540
15

(38)
(25)
(20)
(32)
(1)

96
65
49
82
2

(41)
(28)
(21)
(35)
(1)

110
67
63
113
4

(38)
(23)
(22)
(39)
(1)

354
222
209
265
5

(51)
(32)
(30)
(38)
(1)

476
490
328
378
3

(28)
(29)
(20)
(23)
(<1)

65
62
50
54
1

(28)
(27)
(22)
(23)
(<1)

96
79
35
80
2

(33)
(27)
(12)
(27)
(1)

90
166
278
160
1

(13)
(24)
(40)
(23)
(<1)

1361 (81)
368 (22)

167 (72)
74 (32)

213 (73)
91 (31)

536 (77)
191 (27)

831
194
275
243
129
3

(50)
(12)
(16)
(15)
(8)
(<1)

125
17
38
23
29
0

(54)
(7)
(16)
(10)
(12)
(0)

148
27
48
32
34
3

(51)
(9)
(16)
(11)
(12)
(1)

269
56
108
162
95
5

(39)
(8)
(16)
(23)
(14)
(1)

144
530
130
793
78

(9)
(32)
(8)
(47)
(5)

21
66
14
113
18

(9)
(28)
(6)
(49)
(8)

26
96
15
137
18

(9)
(33)
(5)
(47)
(6)

63
220
77
289
46

(9)
(32)
(11)
(42)
(7)

953
293
75
243
149
140
9
63

(57)
(17)
(4)
(15)
(9)
(8)
(1)
(4)

142
29
15
34
11
20
0
10

(61)
(12)
(6)
(15)
(5)
(9)
(0)
(4)

167
31
11
48
24
24
2
14

(57)
(11)
(4)
(16)
(8)
(8)
(1)
(5)

374
144
39
104
47
65
7
24

(54)
(21)
(6)
(15)
(7)
(9)
(1)
(3)

744
210
380
281
465
84

(44)
(13)
(23)
(17)
(28)
(5)

54
72
57
92
100
11

(23)
(31)
(25)
(40)
(43)
(5)

44
69
122
104
175
14

(15)
(24)
(42)
(36)
(60)
(5)

222
84
238
158
284
38

(32)
(12)
(34)
(23)
(41)
(5)

1573 (94)
102 (6)

221 (95)
11 (5)

282 (97)
10 (3)

659 (95)
36 (5)

Continued
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Table 2. Continued
Prognostic factor

Month of COVID-19 diagnosis
January-April
May-August
September-November
Missing/unknown

No complications

Admitted to hospital

Admitted to ICU

Received mechanical
ventilation

Died within 30 days

(n ¼ 2072, 42%)

(n ¼ 1675, 34%)

(n ¼ 232, 5%)

(n ¼ 292, 6%)

(n ¼ 695, 14%)

627
1177
222
46

(30)
(57)
(11)
(2)

651
842
148
34

(39)
(50)
(9)
(2)

75
129
26
2

(32)
(56)
(11)
(1)

163
115
6
8

(56)
(39)
(2)
(3)

411
245
31
8

(59)
(35)
(4)
(1)

Data presented as n (%) unless otherwise indicated. The ‘Missing/unknown’ category indicates either missingness due to nonresponse for optional survey questions or a response
of unknown; an unknown category was provided for all survey questions.
COVID-19, coronavirus disease 2019; ECOG, Eastern Cooperative Oncology Group; ICU, intensive care unit; IQR, interquartile range.
a
Five-level ordinal scale based on a patient’s most severe reported disease status. For example, patients who were admitted to the intensive care unit without mechanical
ventilation and did not die within 30 days of COVID-19 diagnosis are classiﬁed as ‘admitted to intensive care unit’, whereas patients who were admitted to the intensive
care unit with mechanical ventilation and did not die within 30 days of COVID-19 diagnosis are classiﬁed as ‘received mechanical ventilation’.
b
For patients younger than 18 years, age was truncated to 18 years; for patients older than 89 years, age was truncated to 90 years.
c
Percentages could sum to >100% because categories are not mutually exclusive.
d
Within 3 months of COVID-19 diagnosis.

topic, our ﬁndings are hypothesis generating and might not
directly modify daily clinical practice.
Our ﬁndings conﬁrm those from an earlier study from
CCC19 and other studies.6-10,17 In particular, older age and
male sex have been identiﬁed as negative prognostic factors
among patients with or without cancer, although our study
is the ﬁrst, to our knowledge, to demonstrate a nonlinear
relationship between age and risk.6-10,17,27
We also noted higher COVID-19 severity for patients of
non-Hispanic, non-white race/ethnicity and higher 30-day
mortality for non-Hispanic black patients. These differences may suggest disparities in health care access, delivery,
and research,28 especially in the context of our prior ﬁnding
and a recent systematic review suggesting that nonHispanic black patients were less likely to receive novel
anti-COVID-19 treatments.16,29 Future research from CCC19
is planned to investigate these disparities further.
Among patients with cancer, hematological malignancies,6,8,11 active cancer,6,9-11,17 and worse ECOG PS6,10,17
have been consistently associated with worse outcomes,
which was also noted here. While prior studies observed a
negative association between number of comorbidities and
COVID-19 outcomes,6,7,9 few have investigated speciﬁc
comorbidities as we included in our analysis.
In previous studies among patients without cancer, low
ALC, low platelets, and abnormal CRP and creatinine were
identiﬁed among laboratory values associated with severe
COVID-19.30,31 Data among patients with cancer are limited,
although prior studies suggested that abnormal CRP, LDH,
and low ALC were associated with worse COVID-19 outcomes.10,17 Our study included a broader range of routinely
collected laboratory measurements and identiﬁed new parameters associated with higher COVID-19 severity. However, we did not collect laboratory values now recognized to
be associated with COVID-19 severity (e.g. ferritin32 and
procalcitonin33); future efforts will include automated
extraction of these and longitudinal values directly from
electronic health records.
Receipt of cytotoxic chemotherapy was associated with
higher COVID-19 severity and 30-day mortality. However,
there is substantial variability of anticancer regimens, such
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that no one regimen containing cytotoxics was received by
>31 patients (Figure 2). Some regimens may be subject to
unmeasured confounding, for example, extent of lung
involvement in patients with lung cancer receiving platinum
doublets. It was very concerning to note the high mortality
among those receiving R-CHOP, especially because most
received it with curative intent. While grade 5 toxicities with
R-CHOP may occur,34 a mortality rate >40% is very high.
Although the exact etiology remains unclear, this regimen is
broadly immunosuppressive. In addition to B-cell lymphodepleting effects, rituximab is known to alter the T-cell
compartment, which may contribute to cytokine storm.13,35
On the contrary, the ﬁnding of relatively lower mortality
among patients with multiple myeloma receiving
daratumumab þ IMiD þ corticosteroid seems paradoxical
given the high risk of infection in this patient population.
Interestingly, inhibition of the CD38 pathway may reduce
the inﬂammatory response.36 This relatively favorable
prognosis is supported by several studies.37-39
Notably, immunotherapy alone was not associated with
higher COVID-19 severity. This is in contrast to an earlier
report in lung cancer,40 which was subsequently disproven
after adjustment for smoking status from the same group.41
This ﬁnding is encouraging as immuno-therapeutics (speciﬁcally, immune checkpoint inhibitors) are the most prescribed regimen in our cohort and >40% of patients with
advanced cancer may be eligible for immunotherapy.42
Similarly, endocrine therapy was not associated with
higher COVID-19 severity, after adjustment for cancer status. There is a hypothetical possibility that antiandrogens
could downregulate TMPRSS2 in the lung, limiting SARSCoV-2 infection.13,43 Further investigation is needed.
The pandemic has substantially changed oncology practice in many deleterious ways, which may worsen cancerrelated outcomes.13,44 Since the beginning, clinicians have
attempted to balance the risks and beneﬁts of cancer
therapy by developing consensus-based algorithms to assist
decision making45-48; our data could further guide the
optimization and reﬁnement of those algorithms. Our
ﬁnding of lower COVID-19 severity later in the pandemic
may also suggest an overall improvement in COVID-19 care.
https://doi.org/10.1016/j.annonc.2021.02.024
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Table 3. Adjusted associations of baseline prognostic factors with COVID-19 severity (primary) and 30-day all-cause mortality (secondary) among all patients
COVID-19 severity

30-day mortality

a

OR (95% CI)

ORb (95% CI)

0.91 (0.72-1.15)
1.38 (1.31-1.45)
1.47 (1.31-1.65)

0.58 (0.35-0.97)
1.75 (1.59-1.93)
1.46 (1.20-1.77)

1.46
1.38
1.27
1.10
1.14
1.46
1.52
1.38
1.53

1.38
1.31
0.97
1.20
1.09
1.17
1.34
1.31
1.23

c

Age, per decade
Age <40 years
Age >40 years
Sex, male versus female
Race and ethnicity, versus non-Hispanic white
Non-Hispanic black
Hispanic
Other
Smoking status, ever versus never
Obesity status, obese versus not obese
Cardiovascular comorbidities, yes versus no
Pulmonary comorbidities, yes versus no
Renal disease, yes versus no
Diabetes mellitus, yes versus no
ECOG performance status, versus 0
1
2
Unknown
Type of malignancy, versus solid tumor
Hematological neoplasm
Multipled
Cancer status, versus remission or no evidence of disease
Active and responding
Active and stable
Active and progressing
Unknown
Timing of anticancer therapy, versus >3 months
Never treated
0-4 weeks
1-3 months
Modality of active anticancer therapye
Cytotoxic chemotherapy, yes versus no
Immunotherapy, yes versus no
Targeted therapy, yes versus no
Endocrine therapy, yes versus no
Locoregional therapy, yes versus no
Other, yes versus no
Anti-COVID-19 treatmentf
Remdesivir, yes versus no
HCQ alone, yes versus no
Corticosteroids alone, yes versus no
Other alone, yes versus no
HCQ þ corticosteroids, yes versus no
HCQ þ other, yes versus no
Country of residence, United States versus outside United States
Month of COVID-19 diagnosis, versus January-April
May-August
September-November

(1.27-1.68)
(1.16-1.64)
(1.05-1.53)
(0.98-1.24)
(1.01-1.29)
(1.29-1.67)
(1.33-1.74)
(1.19-1.60)
(1.35-1.73)

(1.09-1.75)
(0.96-1.80)
(0.70-1.36)
(0.98-1.46)
(0.88-1.35)
(0.95-1.43)
(1.09-1.66)
(1.05-1.63)
(1.00-1.50)

1.42 (1.22-1.64)
3.44 (2.88-4.10)
1.75 (1.50-2.04)

1.53 (1.14-2.05)
4.48 (3.34-6.00)
2.04 (1.51-2.76)

1.70 (1.46-1.99)
1.21 (1.01-1.44)

1.44 (1.10-1.87)
1.30 (1.00-1.70)

0.84
0.97
2.19
1.93

0.79
1.06
2.88
2.19

(0.67-1.04)
(0.81-1.16)
(1.80-2.67)
(1.55-2.41)

(0.52-1.18)
(0.77-1.44)
(2.13-3.90)
(1.56-3.07)

1.05 (0.83-1.32)
1.04 (0.79-1.36)
1.03 (0.75-1.41)

1.10 (0.75-1.62)
1.10 (0.70-1.72)
1.39 (0.84-2.29)

1.28
0.86
1.09
0.79
1.18
0.97

(1.04-1.58)
(0.64-1.16)
(0.87-1.36)
(0.61-1.03)
(0.93-1.50)
(0.47-2.00)

1.61
0.91
0.90
0.68
0.96
1.31

(1.15-2.24)
(0.56-1.47)
(0.63-1.31)
(0.43-1.09)
(0.65-1.42)
(0.44-3.94)

d
d
d
d
d
d
1.07 (0.81-1.41)

1.55
1.64
1.86
1.64
1.91
2.98
0.85

(1.10-2.18)
(1.16-2.32)
(1.35-2.56)
(1.23-2.17)
(1.21-3.01)g
(2.24-3.97)g
(0.54-1.35)

0.50 (0.45-0.57)
0.42 (0.34-0.52)

0.43 (0.35-0.54)
0.26 (0.16-0.41)

Models for COVID-19 severity and 30-day all-cause mortality include all variables listed, except where noted. There were no indications of model instability, except for timing of
anticancer therapy (variance inﬂation factor 5.4); however, multicollinearity is not unexpected because timing and modality are both deﬁned by receipt of anticancer therapy.
CI, conﬁdence interval; COVID-19, coronavirus disease 2019; ECOG, Eastern Cooperative Oncology Group; HCQ, hydroxychloroquine; OR, odds ratio.
a
Odds ratios >1 indicate higher COVID-19 severity.
b
Odds ratios >1 indicate higher odds of 30-day all-cause mortality.
c
Obtained from a linear regression spline with a knot at age 40 years, such that odds ratios for ‘Age <40 years’ correspond to the per-decade difference in age for ages <40 years
and odds ratios for ‘Age >40 years’ correspond to the per-decade difference in age for ages >40 years.
d
Includes two or more solid tumors or hematological neoplasms.
e
Within 3 months of COVID-19 diagnosis.
f
The model for COVID-19 severity did include anti-COVID-19 treatments due to suspected confounding by indication.
g
Interaction P ¼ 0.19 (2 degrees of freedom).

Alternative explanations for this ﬁnding include that certain
areas may have been overwhelmed earlier in the pandemic
and that patients prone to severe disease and death,
particularly those in skilled nursing facilities, may have been
infected early. Notably, only 9% of included patients were
diagnosed with COVID-19 during September-November, so
794
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that the observed improvement in outcomes should not be
extrapolated to the surge in November-December 2020.
Ultimately, an individualized riskebeneﬁt discussion is critical when choosing systemic treatment, balancing carefully
risks of cancer progression, associated risk of anticancer
therapy, and COVID-19 severity.
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COVID-19 severity

Outcome

30-day mortality

Absolute lymphocyte count,
high versus normal
Absolute lymphocyte count,
low versus normal
Absolute neutrophil count,
high versus normal
Absolute neutrophil count,
low versus normal
Platelet count, high versus normal
Platelet count, low versus normal
Creatinine, abnormal versus normal
D-dimer, abnormal versus normal
Troponin, abnormal versus normal
Lactate dehydrogenase,
abnormal versus normal
C-reactive protein,
abnormal versus normal
0.25

0.5

1
Odds ratio

2

4

Figure 1. Adjusted odds ratios and 95% conﬁdence intervals for laboratory measurements obtained from multivariable models for COVID-19 severity and 30-day
all-cause mortality among hospitalized patients.
Odds ratios >1 indicate higher COVID-19 severity or higher odds of 30-day all-cause mortality. Adjusted for age, sex, race/ethnicity, country of patient residence, month
of COVID-19 diagnosis, type of malignancy, cancer status, and active anticancer therapy. COVID-19, coronavirus disease 2019.

While the majority of prior studies have suggested poor
outcomes for patients with cancer and COVID-19, a recent
study using a case-matched study design found patients
with cancer and COVID-19 had similar outcomes to those
without cancer, when matched by age, sex, and comorbidities.49 However, this study was limited to hospitalized patients in Manhattan, whereas our cohort includes any
patient with cancer and COVID-19 and is diverse in multiinstitutional representation.
Notable strengths of our study include detailed and
granular information directly collected by health care professionals on a large and geographically diverse patient
population with comprehensive follow-up. The novel ordinal
scale of COVID-19 severity extends our previous research
beyond 30-day mortality to capture other relevant complications of COVID-19 disease, and is consistent with newly
recommended analytical approaches.50 The analysis of
anticancer therapy elucidated speciﬁc regimens associated
with increased mortality, which warrants detailed
exploration.
Our study has several limitations, including those
inherent to a retrospective, observational cohort study.
Volume 32

-

Issue 6

-

2021

Despite a robust data quality assurance system, surveybased data collection (voluntary, uncompensated) across
multiple sites may result in selection biases, reporting errors, missing, and unknown data; the potential impact of
these is mitigated by exclusion of low-quality reports and
multiple imputation. Our results, particularly those for
COVID-19 treatments, may be subject to confounding by
indication and severity.16 Baseline laboratory measurements prior to COVID-19 diagnosis, which have been suggested to be associated with COVID-19 outcomes,51 were
not collected due to the time-intensive nature of manually
recording laboratories; automated data pulls from electronic health records may address this limitation in the
future. Fixed dates are not captured due to the deidentiﬁed
nature of the protocol; therefore time intervals are
approximated at varying levels of granularity. We did not
pursue subset analysis within individual cancer types, which
is an area of future research.
In conclusion, we conﬁrmed high COVID-19 severity and
mortality among patients with cancer, in particular for those
of older age, male sex, non-Hispanic non-white race/
ethnicity, worse ECOG PS, hematologic malignancy, and
https://doi.org/10.1016/j.annonc.2021.02.024
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ERBB2i
Brentuximab vedotin
Bleomycin
Everolimus
EGFR antibody
MEKi
BRAFi
Ifosfamide
Fulvestrant
EGFRi
Temozolomide
Somatostatin analog
PARPi
Cytarabine
VEGFRi
ABRAXANE
JAKi
DNMTi
Hydroxyurea
Venetoclax
CTLA-4 antibody
Pertuzumab
Pemetrexed
Abiraterone
Methotrexate
Daratumumab
CDK4/6i
Irinotecan
BTKi
Gemcitabine
Etoposide
Bevacizumab
Trastuzumab
Oxaliplatin
BCR-ABLi
NSAA
Folinic acid
Proteasome inhibitor
Vinca alkaloid
Tamoxifen
CD20 antibody
IMiD
Cyclophosphamide
Anthracycline
Fluoropyrimidine
Taxane
Corticosteroids
Cisplatin/Carboplatin
ADT/OFS
Aromatase inhibitor
PD-1/PD-L1 antibody
200

150
100
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Total exposures per drug/class

0

Figure 2. Visualization of the most prevalent cancer therapies and associated 30-day all-cause mortality.
Individual anticancer drug exposures and their combinations are shown in an UpSet plot, which is an alternative to the Venn diagram for the visualization of highdimensional data. Each row represents the individual anticancer therapies recorded as being given within 3 months of COVID-19 diagnosis that were present in
10 cases; rows are colored by treatment modality. Each column represents the intersection of one or more drugs given in combination (i.e. as a regimen) in 10 cases.
A column with a single dark circle represents a monotherapy regimen; columns with multiple dark circles connected by dark lines represent multiagent regimens. Bars
are colored by mortality for the patients receiving the drug or the combination, with darker hues representing higher mortality. This information is also shown in tabular
format in Supplementary Table 9, available at https://doi.org/10.1016/j.annonc.2021.02.024.
ADT, androgen-deprivation therapy; BCR-ABLi, BCR-ABL tyrosine kinase inhibitor; BRAFi, serine/threonine-protein kinase B-Raf inhibitor; BTKi, Bruton tyrosine kinase
inhibitor; CDK4/6i, cyclin-dependent kinase 4 and 6 inhibitor; COVID-19, coronavirus disease 2019; DNMTi, DNA methyltransferase inhibitor; EGFRi, epidermal growth
factor receptor tyrosine kinase inhibitor; ERBB2i, epidermal growth factor receptor 2 tyrosine kinase inhibitor; IMiD, immunomodulator; JAKi, Janus kinase inhibitor;
MEKi, mitogen-activated protein kinase kinase inhibitor; NSAA, nonsteroid antiandrogen; OFS, ovarian function suppression; PARPi, poly (ADP-ribose) polymerase inhibitor; VEGFRi, vascular endothelial growth factor receptor inhibitor.

Table 4. Characteristics for exposures associated with the lowesta and highest observed mortality among patients treated with systemic anticancer therapy
within 3 months of COVID-19 diagnosis
Lowest observed mortality

All-cause mortality
30-day mortality
Any mortality
Most common primary cancer
Median (IQR) age, years
ECOG PS 0-1
Curative treatment intent

Highest observed mortality

AC-T-like

Dara-IMiD-Dex

OFS þ AI

Platinum þ Etoposide

R-CHOP-likec

DNMTi

(n ¼ 17)

(n ¼ 10)

(n ¼ 12)

(n ¼ 10)

(n ¼ 22)

(n ¼ 12)

0 (0)
0 (0)
Breast
17 (100)
55 (49-62)
16 (94)
17 (100)

0 (0)
1 (10)
MM
10 (100)
69 (64-80.5)
5 (50)
0 (0)d

0 (0)
0 (0)
Breast
11 (92)
43.5 (41-46.5)
11 (92)
10 (83)

3 (30)
4 (40)
SCLC
5 (50)
66.5 (60-74.5)
6 (60)
2 (20)

8 (36)
10 (45)
DLBCL
17 (77)
67.5 (45-79)
18 (82)
18 (82)

6 (50)
6 (50)
MDS
7 (58)
67.5 (59-87)
7 (58)
1 (8)

b

Data presented as n (%) unless otherwise indicated.
AI, aromatase inhibitor; CDK4/6i, cyclin-dependent kinase 4 and 6 inhibitor; COVID-19, coronavirus disease 2019; Dara, daratumumab; DLBCL, diffuse large B-cell lymphoma;
DNMTi, DNA methyltransferase inhibitor; ECOG PS, Eastern Cooperative Oncology Group performance status; IMiD, immunomodulatory imide drugs; IQR, interquartile range;
MDS, myelodysplastic syndrome; MM, multiple myeloma; OFS, ovarian function suppression; PS, performance status; SCLC, small-cell lung cancer.
a
Not shown: somatostatin analogs, and CDK4/6i þ fulvestrant.
b
Combination of anthracycline, cyclophosphamide, and taxane.
c
Combination of CD20 antibody, cyclophosphamide, anthracycline, vinca alkaloid, and corticosteroid.
d
All treatment for multiple myeloma except allogeneic stem cell transplant was considered palliative by deﬁnition.
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select laboratory measurements. Certain chemotherapy
regimens were associated with high all-cause mortality.
These ﬁndings can inform novel translational research,
clinical trial designs, and clinical decision making for patients with cancer and COVID-19. Future planned work from
CCC19 includes further investigation into health care disparities, outcomes for speciﬁc cancer subtypes, and impact
of particular anticancer therapies.
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